Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Effects of Maternal Fluoxetine Treatment on Anxiety Parameters in the Rat Progeny


Affiliations
1 Neuropharmacology Laboratory, Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221 005, Uttar Pradesh, India
2 Department of Psychology, Mahatma Gandhi Kashi Vidyapith, Varanasi 221002, Uttar Pradesh, India
     

   Subscribe/Renew Journal


Behavioural teratological effects of prenatal fluoxetine exposure were investigated on elevated plus maze and elevated zero maze parameters of anxiety in rats. Pregnant rats were administered fluoxetine (5 and 10 mg/kg/day) orally once a day during the gestation days 13 to 20. The pups born were subjected to elevated plus maze and elevated zero maze tests at 9 weeks of age. The results indicated that maternal fluoxetine treatment (5 and 10 mg/kg/day) induced dose dependent significant decrease in time spent and entries made by rat offspring in open arms of elevated plus maze; and fluoxetine 10 mg treatment also induced significant increase in time spent and entries made by rat offspring in enclosed arms of elevated plus maze. Maternal fluoxetine treatment also caused dose dependent decrease in time spent in open arms and stretched attend postures made by rat offspring in elevated zero maze. The findings demonstrate that maternal fluoxetine treatment caused enhanced anxiogenic behaviour patterns the rat offspring.

Keywords

Fluoxetine, Elevated Plus Maze, Elevated Zero Maze, Prenatal, Rat.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Noble RE: Depression in women. Metabolism. 2005: 54: 49–52.

  • Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R: Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008; 198:e191–e195.

  • Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C: Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63: 898–906.

  • Cooper WO, Willy ME, Pont SJ, Ray WA: Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007; 196:e541–e545.

  • Nulman I, Koren G. The safety of fluoxetine during pregnancy and lactation. Teratology, 1996; 53: 304.

  • Noorlander CW, Ververs FFT, Nikkels PGJ, van Echteld CJA, Visser GHA, Smidt MP:Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One 2008; 3:e2782.

  • Olivier JDA, Valles A, van Heesch F, Afrasiab- Middelman A, Roelofs JJPM, Jonkers M, Peeters EJ, Korte-Bouws GAH, Dederen JP, Kiliaan AJ, Martens G, Schubert D, Homberg J: Fluoxetine administration to pregnant rats increases anxietyrelated behavior in the offspring. Psychopharmacology (Berl) 2011; 217:419–432.

  • Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, Buelke-Sam J: A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994; 23: 194–205.

  • Da Silva VA, Altenburg SP, Malheiros LR, Thomaz TG, Lindsey CJ: Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. Braz J Med Biol Res 1999; 32: 93–98.

  • Bauer S, Monk C, Ansorge M, Gyamfi C, Myers M: Impact of antenatal selective serotonin reuptake inhibitor exposure on pregnancy outcomes in mice. Am J Obstet Gynecol 2010; 203:e371–e374.

  • Müller JC, Boareto AC, Lourenco ELB, Zaia RM, Kienast MF, Spercoski KM, Morais RN, Martino-Andrade AJ, Dalsenter PR: In utero and lactational exposure to fluoxetine in Wistar rats: pregnancy outcomes and sexual development. Basic Clin Pharmacol Toxicol 2013; 113: 132–140.

  • Bairy KL, Madhyastha S, Ashok KP, Bairy I, Malini S: Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 2007; 79: 1–11.

  • Cagiano R, Flace P, Bera I, Maries L, Cioca G, Sabatini R, Benagiano V, Auteri P, Marzullo A, Vermesan D, Stefanelli R, Ambrosi G: Neurofunctional effects in rats prenatally exposed to fluoxetine. Eur Rev Med Pharmacol Sci 2008; 12: 137–148.

  • Cabrera TM, Battaglia G: Delayed decreases in brain 5-hydroxytryptamine2A/2C receptor density and function in male rat progeny following prenatal fluoxetine. J Pharmacol Exp Ther 1994; 269: 637–645.

  • Bellantuono, C., Migliarese, G., and Gentile, S. (2007). Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: A systematic review. Human Psychopharmacology: Clinical and Experimental, 22, 121-128.

  • Chambers, C. D., Johnson, K. A., Dick, L. M., Felix, R. J., and Jones, K. L. (1996). Birth outcomes in pregnant women taking fluoxetine. New England Journal of Medicine, 335(14), 1010-1015. doi:10.1056/NEJM199610033351402

  • Goodman, S.H. and Gotlib, I.H. (1999). Risk for psychopathology in the children of depressed parents: A developmental approach to the understanding of mechanisms. Psychological Review, 106, 458-490.

  • Lisboa SF, Oliveira PE, Costa LC, Venancio EJ, Moreira EG: Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 2007; 80: 49–56.

  • McAllister BB, Kiryanova V, Dyck RH: Behavioural outcomes of perinatal maternal fluoxetine treatment. Neuroscience 2012; 226:356–366.

  • Karpova NN, Lindholm J, Pruunsild P, Timmusk T, Castrén E: Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol 2009; 19: 97–108.

  • Rozenthal M, Laks J, and Engelhardt E. Neuropsychological aspects of depression. Revista de Psiquiatria do Rio Grande do Sul, 2004; 26: 204-212.

  • Swerts CAS, Costa AMDD, Esteves A, Borato CES, and Swerts MSO. Effects of fluoxetine and imipramine in rat fetuses treated during a critical gestational period: A macro and microscopic study. Revista Brasileira De Psiquiatria (São Paulo,Brazil: 1999), 2010; 32: 152-158.

  • Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995; 15:417–420.

  • Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, Gardner A, Hom M, Koren G. Pregnancy outcome following first trimester exposure to fluoxetine (Prozac). JAMA 1993; 269:2246–2248.

  • Ericson A, Kallen B, Wiholm BE: Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55:503–508.

  • Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JGW, Kulin N, Koren G. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336:258– 262.

  • Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335:1010–1015.

  • Holson RR, Pearce B. Principles and pitfalls in the analysis of prenatal treatment effects in multiparous species. Neurotoxicol. Teratol. 1992; 14: 221-228.

  • Pellow S, File SE. Anxiolytics and anxiogenic drug effects in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav. 1986; 24: 525-529.

  • Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. Behavioural and pharmacological characterization of the elevated “zero maze” as an animal model of anxiety. Psychopharmacology. 1994; 116: 56-64.

  • Johnston AL, Baldwin HA, File SE. Measures of anxiety and stress in the rat following chronic treatment with yohimbine. J Psychopharmacol 1988; 2:33-38.

  • Winer BJ. Statistical principles in experimental design. McGrawHill, New York, 1962.

  • Forcelli PA, Heinrichs SC: Teratogenic effects of maternal antidepressant exposure on neural substrates of drug-seeking behavior in offspring. Addict Biol 2008; 13: 52–62.

  • Zheng J, Xu D-F, Li K, Wang H-T, Shen P-C, Lin M, Cao X-H, Wang R: Neonatal exposure to fluoxetine and fluvoxamine alters spine density in mouse hippocampal CA1 pyramidal neurons. Int J Clin Exp Pathol 2011; 4:162–168.

  • Lee L-J, Lee LJ-H: Neonatal fluoxetine exposure alters motor performances of adolescent rats. Dev Neurobiol 2012; 72: 1122– 1132.

  • Capello CF, Bourke CH, Ritchie JC, Stowe ZN, Newport DJ, Nemeroff A, Owens MJ: Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk. J Pharmacol Exp Ther 2011; 339: 275–285.

  • Nagano M, Liu M, Inagaki H, Kawada T, Suzuki H: Early intervention with fluoxetine reverses abnormalities in the serotonergic system and behavior of rats exposed prenatally to dexamethasone. Neuropharmacology 2012; 63: 292–300.

  • Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA: Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004; 306: 879–881.

  • Ansorge MS, Morelli E, Gingrich JA: Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci 2008; 28: 199–207.

  • Smit-Rigter LA, Noorlander CW, von Oerthel L, Chameau P, Smidt MP, van Hooft JA: Prenatal fluoxetine exposure induces lifelong serotonin 5-HT 3 receptor-dependent cortical abnormalities and anxiety-like behaviour. Neuropharmacology 2012; 62: 865–870.

  • Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE: Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142:402–408.

  • Wisner KL, Sit DKY, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, Perel JM, Jones-Ivy S, Bodnar LM, Singer LT: Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166: 557–566.

  • Morrison JL, Chien C, Gruber N, Rurak D, Riggs W: Fetal behavioural state changes following maternal fluoxetine infusion in sheep. Brain Res Dev Brain Res 2001; 131: 47–56.

  • Cabrera-Vera TM, Garcia F, Pinto W, Battaglia G: Effect of prenatal fluoxetine (Prozac) exposure on brain serotonin neurons in prepubescent and adult male rat offspring. J Pharmacol Exp Ther 1997; 280: 138–145.

  • Silva CMd, Gonçalves L, Manhaes-de-Castro R, Nogueira MI: Postnatal fluoxetine treatment affects the development of serotonergic neurons in rats. Neurosci Lett 2010; 483: 179–183.

  • Cabrera-Vera TM, Battaglia G: Prenatal exposure to fluoxetine (Prozac) produces sitespecific and age-dependent alterations in brain serotonin transporters in rat progeny: evidence from autoradiographic studies. J Pharmacol Exp Ther 1998; 286: 1474–1481.

  • Singh Y, Jaiswal AK, Singh M and Bhattacharya SK. Behavioural effects of prenatal diazepam administration on anxiety patterns in rats. Indian J Exp Biol, 1996; 34: 1095-1099.

  • Singh Y, Jaiswal AK, Singh M and Bhattacharua SK. Effect of prenatal haloperidol administration on anxiety patterns in rats. Indian J Exp Biol, 1997; 35: 1284-1290.

  • Jaiswal AK, Bhattacharya SK. Effect of prenatal undernutrition and phenobarbitone administration on discrimination learning and passive avoidance behaviour in rats. Indian J Exp Biol, 1996; 34: 118-123.

  • Jaiswal AK, Bhattacharya SK. Effect of gestational undernutrition and chlordiazepoxide treatment on black/white discrimination learning and retention in young rats. Indian J Exp Biol, 1994; 32: 184-188.

  • Reis M, Kallen B: Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723–1733.

  • Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH: Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. Br Med J 2009; 339:b3569.

  • Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nielsen RB, Norgaard M, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B: Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ (Clin Res Ed) 2012; 344:d8012.

  • Fornaro E, Li D, Pan J, Belik J: Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med 2007; 176: 1035–1040.


Abstract Views: 273

PDF Views: 0




  • Effects of Maternal Fluoxetine Treatment on Anxiety Parameters in the Rat Progeny

Abstract Views: 273  |  PDF Views: 0

Authors

Singh Yogita
Neuropharmacology Laboratory, Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221 005, Uttar Pradesh, India
Jaiswal Arun Kumar
Department of Psychology, Mahatma Gandhi Kashi Vidyapith, Varanasi 221002, Uttar Pradesh, India

Abstract


Behavioural teratological effects of prenatal fluoxetine exposure were investigated on elevated plus maze and elevated zero maze parameters of anxiety in rats. Pregnant rats were administered fluoxetine (5 and 10 mg/kg/day) orally once a day during the gestation days 13 to 20. The pups born were subjected to elevated plus maze and elevated zero maze tests at 9 weeks of age. The results indicated that maternal fluoxetine treatment (5 and 10 mg/kg/day) induced dose dependent significant decrease in time spent and entries made by rat offspring in open arms of elevated plus maze; and fluoxetine 10 mg treatment also induced significant increase in time spent and entries made by rat offspring in enclosed arms of elevated plus maze. Maternal fluoxetine treatment also caused dose dependent decrease in time spent in open arms and stretched attend postures made by rat offspring in elevated zero maze. The findings demonstrate that maternal fluoxetine treatment caused enhanced anxiogenic behaviour patterns the rat offspring.

Keywords


Fluoxetine, Elevated Plus Maze, Elevated Zero Maze, Prenatal, Rat.

References